BCPS Exam Flashcards

Q: What is the BCPS exam pass rate?

BPS does not publish a single blanket rate, but its 2025 continuous testing results report a 55.9% pass rate for first-time BCPS candidates and 51.3% across all candidates (including retakes) out of 2,308 total examinees. Rates vary by year and eligibility pathway (practice experience vs. PGY1 residency).

Q: What are the BCPS exam domains and weights?

Per the BPS Examination Specifications effective September 2024: Patient Care Specialty Areas (36%), Therapeutics and Patient Management (36%), and Professional Practice (28%). The first two domains together account for 72% of the exam, reflecting a strong emphasis on applied clinical decision-making over pure knowledge recall.

Q: What happens if I fail the BCPS exam?

Candidates get up to two retakes (three attempts total per certification cycle). After each attempt, BPS requires a 90-day washout period before you can schedule the next attempt, and the retake fee is $300. If you don't pass after the third attempt, you must wait 12 months from your last attempt before submitting a brand-new application and paying the full $600 fee again.

Q: Why is pharmacokinetics (PK) so heavily tested on the BCPS exam?

PK concepts (volume of distribution, first-order vs. zero-order kinetics, half-life, loading dose calculations) sit inside the Treatment Planning subarea of the Therapeutics and Patient Management domain (36% of the exam) and recur throughout patient-care vignettes on drugs like vancomycin, phenytoin, digoxin, and lithium. Strong PK fundamentals let you solve dosing and monitoring questions across nearly every specialty area, not just one topic.

Q: How often do I need to recertify BCPS, and what does it require?

BCPS certification must be renewed every 7 years. Certificants can either retake and pass the recertification exam (plus report continuing professional development units for cycles beginning in 2024 or later) or complete a BPS-approved Professional Development Program through ACCP or ASHP instead of retesting.

Question 1

What is the target AUC24 for vancomycin dosing in serious MRSA infections?

Accepted Answer

AUC24/MIC of 400-600 mg*h/L (assuming MIC=1) is the current consensus target, replacing trough-only monitoring; a trough of 15-20 mg/L is still used as a practical surrogate for serious infections when AUC-based dosing software isn't available.

Question 2

Why is daptomycin inactivated in the lungs and unsuitable for pneumonia?

Accepted Answer

Pulmonary surfactant binds and inactivates daptomycin, so it cannot treat community- or hospital-acquired pneumonia even against susceptible organisms; choose vancomycin or linezolid instead for MRSA pneumonia.

Question 3

A patient has a severe C. difficile infection. What is first-line therapy?

Accepted Answer

Oral vancomycin or fidaxomicin is first-line for an initial C. diff episode; fidaxomicin is favored by current IDSA/SHEA guidance for its lower recurrence rate. IV/oral metronidazole is reserved as an adjunct for fulminant disease.

Question 4

How high is true cross-reactivity between penicillins and cephalosporins in a patient with a non-severe penicillin allergy history?

Accepted Answer

Generally cited as under 1-2%, driven mainly by shared R1 side chains rather than the beta-lactam ring itself; most patients with a reported penicillin allergy can safely receive cephalosporins after appropriate risk assessment.

Question 5

What INR range is the target for standard warfarin therapy (e.g., atrial fibrillation, VTE treatment)?

Accepted Answer

2.0-3.0 is the standard therapeutic range for most warfarin indications, including nonvalvular atrial fibrillation and venous thromboembolism treatment.

Question 6

What INR range applies to a patient with a mechanical mitral valve?

Accepted Answer

2.5-3.5 is the target for mechanical mitral valves (and higher-risk mechanical aortic valves), set higher than the standard 2-3 range because mitral prostheses carry greater thrombogenic risk.

Question 7

Name the four guideline-directed medical therapy drug classes ('four pillars') for HFrEF.

Accepted Answer

ARNI (or ACEI/ARB if ARNI isn't feasible), an evidence-based beta-blocker, an MRA, and an SGLT2 inhibitor. All four should be initiated and up-titrated in parallel for HFrEF (EF <=40%) to reduce mortality and hospitalizations.

Question 8

What doses define 'high-intensity' statin therapy?

Accepted Answer

Atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily; these regimens are expected to lower LDL-C by 50% or more and are used for clinical ASCVD, LDL-C >=190 mg/dL, and diabetic patients age 40-75 with additional risk factors.

Question 9

Which equation is standard for renal drug-dosing decisions, and which for CKD staging?

Accepted Answer

Cockcroft-Gault estimates creatinine clearance and is the standard reference for drug-dosing adjustments since most package inserts were validated against it. CKD-EPI estimates GFR and is preferred for staging chronic kidney disease.

Question 10

Below what creatinine clearance should metformin generally be avoided?

Accepted Answer

CrCl below 30 mL/min is a contraindication due to lactic acidosis risk; dose reduction and closer monitoring are recommended once CrCl falls below 45 mL/min, per current FDA labeling.

Question 11

What is the recommended first-line approach to chronic non-cancer pain under current guidelines?

Accepted Answer

Non-opioid and non-pharmacologic therapies (NSAIDs, acetaminophen, physical therapy, exercise, CBT) are preferred first-line; opioids are reserved for situations where expected benefits outweigh risks after other options are inadequate.

Question 12

What lactate level and antibiotic timing anchor the sepsis 'hour-1' resuscitation bundle?

Accepted Answer

A lactate above 2 mmol/L signals hypoperfusion and should be remeasured; broad-spectrum antibiotics should be given within 1 hour of sepsis recognition, along with 30 mL/kg crystalloid for hypotension or lactate >=4 mmol/L.

Question 13

What is the first-line vasopressor for septic shock?

Accepted Answer

Norepinephrine is first-line; vasopressin or epinephrine may be added as a second agent if the mean arterial pressure goal (>=65 mmHg) isn't reached on norepinephrine alone.

Question 14

What is first-line drug therapy for terminating status epilepticus?

Accepted Answer

IV benzodiazepines (lorazepam or diazepam) are first-line; if seizures persist, a second-line agent (IV fosphenytoin, valproate, or levetiracetam) is given next, as these three showed comparable efficacy in the ESETT trial.

Question 15

What is the antidote for acetaminophen toxicity, and when is it most effective?

Accepted Answer

N-acetylcysteine (NAC) is the antidote; it is most effective when started within 8 hours of ingestion, guided by the Rumack-Matthew nomogram, but is still given later for delayed presentations or staggered/unknown-time overdoses.

Question 16

What is the classic triad of serotonin syndrome?

Accepted Answer

Autonomic instability (hyperthermia, tachycardia, diaphoresis), neuromuscular abnormalities (clonus, hyperreflexia, tremor), and altered mental status. Management is supportive care plus stopping serotonergic agents; cyproheptadine is used for severe cases.

Question 17

What ANC threshold and temperature define febrile neutropenia requiring empiric broad-spectrum antibiotics?

Accepted Answer

ANC below 500 cells/mm3 (or below 1000 with an expected drop below 500) plus a single temperature >=38.3 C (or >=38.0 C sustained over an hour) defines febrile neutropenia, warranting empiric antipseudomonal beta-lactam therapy within 1 hour.

Question 18

Why are ACE inhibitors and ARBs contraindicated in pregnancy?

Accepted Answer

They are teratogenic, particularly in the second and third trimesters, causing fetal renal dysgenesis, oligohydramnios, and skull/limb defects; they should be discontinued as soon as pregnancy is confirmed or planned.

Question 19

What does volume of distribution (Vd) represent, and what does a very high Vd (e.g., greater than 1 L/kg) suggest about a drug?

Accepted Answer

Vd is a theoretical constant relating total drug in the body to plasma concentration, not a real physical volume. A high Vd (e.g., digoxin, amiodarone) suggests extensive tissue/lipid distribution and means the drug is poorly removed by dialysis or plasma exchange.

Question 20

Distinguish first-order from zero-order elimination kinetics.

Accepted Answer

First-order: a constant fraction of drug is eliminated per unit time, so half-life stays constant regardless of dose (most drugs). Zero-order: a constant amount is eliminated per unit time because the elimination pathway is saturated (e.g., phenytoin, high-dose aspirin, ethanol), so half-life increases as dose increases.

Question 21

About how many half-lives does it take to reach steady state on a fixed dosing regimen?

Accepted Answer

Approximately 4-5 half-lives, regardless of the dose or dosing interval, because time to steady state depends only on the elimination half-life (assuming first-order kinetics and no loading dose).

Question 22

What is the formula for calculating a loading dose?

Accepted Answer

Loading dose = Vd x target plasma concentration (divided by bioavailability F for oral dosing). Loading doses bypass the 4-5 half-life wait for steady state when a rapid therapeutic level is needed, as with vancomycin, phenytoin, or digoxin.

Question 23

In shared decision-making with an elderly patient of limited life expectancy, how should 'time to benefit' shape a treatment decision?

Accepted Answer

Time to benefit compares how long a therapy needs to produce measurable benefit against the patient's expected survival and goals of care; preventive therapies with long time-to-benefit (e.g., a statin for primary prevention) may be deprioritized if the patient is unlikely to live long enough to gain from them.

Question 24

Which route of administration has the fastest onset of action, and why?

Accepted Answer

IV push/bolus, because it bypasses absorption entirely and delivers 100% bioavailability directly into systemic circulation, which is why emergency medications are given IV.

Question 25

Why is oral bioavailability usually less than 100%?

Accepted Answer

Oral drugs undergo first-pass hepatic (and sometimes gut wall) metabolism before reaching systemic circulation, reducing the fraction of the administered dose that becomes bioavailable; IV drugs have 100% bioavailability by definition.

Question 26

At what points in a patient's care should medication reconciliation be performed?

Accepted Answer

At every transition of care - hospital admission, transfer between units or levels of care, and discharge - comparing the patient's current medication list against newly ordered medications to resolve discrepancies and prevent adverse events.

Question 27

Name common categories of 'high-alert' medications requiring extra safeguards.

Accepted Answer

Insulin, anticoagulants (warfarin, heparin, DOACs), opioids, concentrated electrolytes (e.g., potassium chloride), and chemotherapy agents - ISMP designates these as high-alert because errors with them are more likely to cause serious patient harm.

Question 28

What is 'tall man lettering' used for?

Accepted Answer

It highlights distinguishing letters in look-alike drug names (e.g., hydrOXYzine vs. hydrALAZINE, DOPamine vs. DOBUTamine) to reduce selection errors caused by name confusion during prescribing, dispensing, and administration.

Question 29

What is the 'teach-back' method, and why is it used in patient counseling?

Accepted Answer

Teach-back asks patients to restate instructions in their own words (e.g., 'how will you take this medication?') to confirm understanding; it catches gaps in health literacy or comprehension before they cause nonadherence or medication errors.

Question 30

Which drugs are classic candidates for therapeutic drug monitoring (TDM) due to a narrow therapeutic index?

Accepted Answer

Vancomycin, aminoglycosides (gentamicin, tobramycin), phenytoin, lithium, digoxin, and warfarin (via INR) - small changes in dose or clearance for these drugs can quickly cause toxicity or treatment failure.

Question 31

What is lithium's typical therapeutic serum level range, and why does monitoring matter so much?

Accepted Answer

0.6-1.2 mEq/L is the typical maintenance range (up to about 1.5 for acute mania). Lithium has a narrow therapeutic index, and levels rise with renal impairment, low sodium intake, and interacting drugs like NSAIDs, ACE inhibitors, and thiazide diuretics.

Question 32

Above what digoxin level is toxicity typically a concern?

Accepted Answer

Above 2 ng/mL is generally considered toxic, though toxicity can occur within the broader 'therapeutic' range (roughly 0.5-2 ng/mL) especially with hypokalemia, hypomagnesemia, or renal impairment, which increase myocardial sensitivity to digoxin.

Question 33

Distinguish an adverse drug event (ADE) from an adverse drug reaction (ADR).

Accepted Answer

An ADE is any harm resulting from medication use, including preventable errors (e.g., a wrong dose) - a broad umbrella term. An ADR is a narrower subset: an unintended, noxious response occurring at normal doses used for prophylaxis, diagnosis, or therapy, not caused by an error.

Question 34

Name several strong CYP3A4 inhibitors a pharmacist should flag for a patient on a CYP3A4 substrate like a statin or a DOAC.

Accepted Answer

Azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), protease inhibitors (ritonavir), and grapefruit juice are classic CYP3A4 inhibitors that can raise substrate drug levels and toxicity risk.

Question 35

How is medication adherence typically measured from pharmacy claims data, and what cutoff usually defines 'good' adherence?

Accepted Answer

Proportion of Days Covered (PDC) or Medication Possession Ratio (MPR), calculated from refill data, are the standard measures; a PDC/MPR of 80% or higher is the widely used threshold for adequate adherence in chronic disease quality metrics like Medicare Star Ratings.

Question 36

Why should a clinician confirm a therapeutic endpoint rather than just a drug level being 'in range'?

Accepted Answer

Therapeutic endpoints are clinical or surrogate markers tied directly to the treatment goal (A1c for glycemic control, INR for anticoagulation, blood pressure for hypertension); a drug level being in range doesn't guarantee the clinical response has actually been achieved.

Question 37

What is the difference between a 'near miss' and a 'sentinel event' in medication safety reporting?

Accepted Answer

A near miss (or 'good catch') is an error intercepted before reaching the patient, so no harm occurs. A sentinel event is a patient safety event resulting in death, permanent harm, or severe temporary harm requiring intervention - both should be reported to drive system-level improvement.

Question 38

What is the purpose of a clinical practice guideline (CPG), and what limits how directly it applies to one patient?

Accepted Answer

CPGs synthesize evidence into recommendations for a typical patient with a given condition; they must be individualized for comorbidities, patient preferences, limited life expectancy, and situations the underlying trials excluded, such as frail elderly or multimorbid patients.

Question 39

A pharmacist discovers a colleague diverting controlled substances. What ethical obligation applies?

Accepted Answer

Pharmacists have a duty to report suspected diversion through appropriate channels (supervisor, state board of pharmacy, DEA) to protect patient safety and public trust; professional ethics codes require action over silence, even when reporting a colleague.

Question 40

What does 'continuity of care' require at hospital discharge?

Accepted Answer

Clear communication of medication changes, follow-up appointments, and monitoring plans to the patient, caregivers, and outpatient providers - typically via a discharge summary plus medication reconciliation - to prevent readmissions caused by care-transition errors.

Question 41

What is a key preventive care service pharmacists commonly provide as part of public health efforts?

Accepted Answer

Immunizations (influenza, pneumococcal, zoster, COVID-19, and others), along with screenings (blood pressure, A1c, cholesterol) and counseling such as smoking cessation - pharmacist-administered vaccination is a major public health access point.

Question 42

Why do quality programs track 'never events' separately from other adverse events?

Accepted Answer

Never events are serious, largely preventable patient safety incidents that should not occur if safeguards are followed (e.g., wrong-patient or wrong-drug administration); tracking them separately drives root-cause analysis and targeted systemic fixes rather than being averaged into general error rates.

Question 43

How is Number Needed to Treat (NNT) calculated, and how should it be interpreted?

Accepted Answer

NNT = 1 / Absolute Risk Reduction (ARR). It's the number of patients who must be treated to prevent one additional bad outcome - a lower NNT indicates a more impactful treatment effect.

Question 44

How is Number Needed to Harm (NNH) calculated, and how should it be interpreted relative to NNT?

Accepted Answer

NNH = 1 / Absolute Risk Increase (ARI). It's the number of patients treated before one additional patient experiences harm - a higher NNH is safer. Weighing NNT against NNH helps assess a therapy's overall benefit-risk balance.

Question 45

Explain the mnemonics SnNout and SpPin for interpreting diagnostic test results.

Accepted Answer

SnNout: a highly SeNsitive test, when Negative, rules OUT disease (few false negatives). SpPin: a highly SPecific test, when Positive, rules IN disease (few false positives). Use sensitive tests to screen and specific tests to confirm.

Question 46

Where does a randomized controlled trial (RCT) sit in the hierarchy of levels of evidence, and what outranks it?

Accepted Answer

RCTs rank near the top of primary study designs, above cohort, case-control, and other observational studies, because randomization minimizes confounding and bias. A systematic review or meta-analysis pooling multiple RCTs ranks above any single RCT.

Question 47

What is the purpose of a Medication Use Evaluation (MUE)?

Accepted Answer

An MUE is a structured, ongoing review of prescribing, dispensing, and administration practices for a specific drug or drug class against defined criteria, used to identify and correct patterns of inappropriate use and improve outcomes and cost-effectiveness.

Question 48

What is the core benefit of pairing Computerized Provider Order Entry (CPOE) with clinical decision support (CDS)?

Accepted Answer

CPOE lets providers enter orders directly into the EHR, reducing transcription and handwriting errors; paired CDS delivers real-time alerts for drug interactions, allergies, and renal dosing at the point of prescribing, catching errors before they reach the patient.

Question 49

In pharmacoeconomics, what does a cost-effectiveness analysis compare, and what is its typical output?

Accepted Answer

It compares the costs and health outcomes of two or more interventions, expressed as an incremental cost-effectiveness ratio (ICER) - often dollars per additional quality-adjusted life year (QALY) gained - to guide formulary placement and coverage decisions.

Question 50

What is a pharmacist's role in institutional emergency preparedness planning?

Accepted Answer

Maintaining emergency medication caches and formularies, ensuring continuity of medication supply during disasters, participating in mass-casualty and pandemic response protocols, and coordinating with public health authorities on stockpile distribution.

Free BCPS Exam Flashcards

Filter by Topic

Jump to Card

About These BCPS Flashcards

Topics Covered

Frequently Asked Questions

BCPS

Explore More BPS Pharmacy Specialty Certifications

BCOP Board Certified Oncology Pharmacist

BCACP

BCCCP

BCEMP Board Certified Emergency Medicine Pharmacist

BCPP

BCPPS Board Certified Pediatric Pharmacy Specialist

More From This Family